AtaiBeckley (ATAI) Proxy filing summary

Executive summary

• A definitive merger agreement was reached for a wholly owned subsidiary of Eli Lilly to merge with and acquire all outstanding shares of common stock of the target for $6.75 per share in cash, plus up to $2.50 per share in contingent value rights (CVRs) tied to clinical and regulatory milestones for key drug candidates.

• The board of directors of the target unanimously approved the merger agreement and recommends shareholder approval; key shareholders and all directors and officers have signed voting and support agreements covering about 15% of outstanding shares.

• The transaction values the target at approximately $2.8 billion upfront, with an additional potential $1.0 billion in CVR payments, and is expected to close in the third quarter, subject to shareholder and regulatory approvals.

• The merger expands the acquirer's neuroscience pipeline, particularly in treatment-resistant depression, and is not subject to any financing condition.

Voting matters and shareholder proposals

• Shareholders will vote on the adoption of the merger agreement at a special meeting; the proxy statement will be mailed after SEC clearance.

• Voting and support agreements require signatories to vote in favor of the merger and restrict transfers of shares, with exceptions for certain permitted transfers.

• The only matters to be acted on at the meeting are the merger, a non-binding advisory compensation vote, and adjournment.

Board of directors and corporate governance

• The board unanimously determined the merger is fair and in the best interests of shareholders and received fairness opinions from two financial advisors.

• At closing, the certificate of incorporation and bylaws will be amended and restated; directors and officers of the surviving corporation will be those of the acquirer's subsidiary.

• Directors and officers of the target will resign at the effective time.